Pfizer Vs. Johnson & Johnson: Determining The Superior Investment Value

Related Articles

Is Johnson & Johnson's $1 Billion Cell Therapy Investment a Game Changer

8 months ago

Why is Johnson & Johnson Selling its Orthopedics Unit

8 months ago

Johnson & Johnson's "New Era" of Growth: Why the Market Underestimates Its Innovative Pipeline

4 months ago

What's Driving Johnson Controls' Recent Momentum Ahead of Q2 Earnings

6 months ago

Category

You may also like

Stock News•3 weeks ago

Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation

Pfizer trades at a cheaper valuation and higher yield than J&J, but J&J's diversified portfolio, new drug launches and sales growth give it an edge, per the comparison.

PFE

Share

Stock News•3 months ago

Pfizer: Calling The Bottom - The Patent Cliff Is Real, But The Valuation Has Fallen Too Far

Pfizer initiated with a contrarian BUY rating and $32 price target for 2026 Q3-Q4, as non-COVID portfolio resilience offsets patent cliff pressures.

PFE

Share

Stock News•3 months ago

Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories

Johnson & Johnson and Abbott Laboratories posted earnings showing diverging strategic paths, with JNJ facing headwinds from talc litigation and ABT benefiting from medical device growth.

ABT

Share